AVRO News and Press, AVROBIO Inc. From 08/13/21

The following slide deck was published by AVROBIO, Inc. in conjunction with this event. For further details see: Avrobio (AVRO) Investor Presentation - Slideshow

Gainers: Golden Nugget Online Gaming (NASDAQ:GNOG) +48%. Tarena International (NASDAQ:TEDU) +43%. SCWorx (NASDAQ:WORX) +32%. Select Interior Concepts (NASDAQ:SIC) +30%. Washington Prime Group (NYSE:WPG) +30%. The9 Limited (NASDAQ:NCTY) +27%. Sphere 3D (NASDAQ:ANY) +26%. Liminal BioSciences (N...

AVROBIO (NASDAQ:AVRO): Q2 GAAP EPS of -$0.74 misses by $0.08. As of June 30, 2021, AVROBIO had $226.4 million in cash and cash equivalents, as compared to $259.7 million in cash and cash equivalents as of Dec. 31, 2020. Press Release For further details see: AVROBIO EPS misses by $0.08 ...

U.S. Food and Drug Administration granted Fast Track Designation to AVR-RD-04 for cystinosis Company is planning to initiate multiple registration trials in 2022 Multiple data and regulatory updates anticipated over next 12 months AVROBIO, Inc . (Nasdaq: ...

AVROBIO, Inc . (Nasdaq: AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced that members of its senior management team are scheduled to participate in two upcoming investor conferences: BTIG Vir...

AVROBIO, Inc. (Nasdaq:AVRO), a leading clinical-stage gene therapy company with a mission to free people from a lifetime of genetic disease, today announced Geoff MacKay, president and CEO of AVROBIO, will present at the JMP Securities Life Sciences Conference at 10:30 a.m. ET on Th...

AVROBIO ([[AVRO]] +8.6%) has risen sharply today as Needham initiated the coverage of the stock with a buy rating. The price target of $28.00 per share implies ~247.8% upside from the last close.Analyst Gil Blum estimates over $2B peak sales from its clinical programs targeting lysosomal stor...

Political change along with updated White House priorities have certainly created a need to review investment portfolios. As the national focus shifts from one area of fulfilling citizens' wants and needs to another, some industries are getting more attention while others are put on “hi...

Held meeting with the U.S. Food and Drug Administration (FDA) to discuss the regulatory path for AVR-RD-01 for Fabry disease Dosing completion in ongoing FAB-GT Phase 2 trial reaches 50%, with three additional patients dosed in three months AVROBIO, Inc . (Nasdaq...

AVROBIO's competing drug Fabrazyme received full approval, resulting in a 2-year delay for AVRO. However, there are silver linings here in the bad news. One of those is the current depressed price. For further details see: AVROBIO: Fabrazyme's Full Approval Changes Thing...